Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen is on track to achieve an annual revenue run-rate of $70-73M by the end of 2026, with a projected 5-10% year-over-year revenue growth. This growth is driven by the success of the company's expanded sales force and new biomarker launches, which have led to a 10% increase in volume and a 1% increase in ASPs in the first quarter of 2026. The company's focus on diagnostic testing for chronic autoimmune diseases, combined with its pipeline of new tests and strong management team, make it an attractive investment opportunity for investors with a long-term outlook.

Bears say

Exagen is facing headwinds due to a significant loss of a direct bill account, which is expected to have a $25 impact on trailing-twelve-month average selling price (ASP) over the coming quarters. This is expected to reset the company's quarterly ASP to a new base and contribute to Y/Y ASP declines. Additionally, the company's goal of reaching a $500/test ASP may be delayed to 2H27, and continued low single-digit sequential growth in quarterly ASP is expected throughout 2026. As a result, the company's revenue and free cash flow may be impacted, leading to a lowered 2026 growth outlook and a decline in peer multiples, resulting in a lowered price target from $18 to $8.

Exagen Inc (XGN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.